Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Neutropenia 1Neoplasms 1Breast Neoplasms 1

Interventions

pegfilgrastim 13Filgrastim 13Cytarabine 5Cyclophosphamide 5pegylated granulocyte colony-stimulating factor 4Etoposide 4Methotrexate 3Doxorubicin 3Docetaxel 3trifluridine tipiracil drug combination 2Vincristine 2Daunorubicin 2Cisplatin 2Amifostine 2trilaciclib 1niraparib 1lintuzumab 1leridistim 1isavuconazole 1fludarabine phosphate 1fish oil triglycerides 1etoposide phosphate 1eravacycline 1eflapegrastim 1angiotensin I (1-7) 1Voriconazole 1Vegetables 1Topotecan 1Thioguanine 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neutropenia × Maxy G34 × Clear all
NCT00501332 2007-12-24

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy

Maxygen Holdings Ltd.

Phase 2 Unknown
30 enrolled
Breast

Breast Neoplasms, Neoplasms, Neutropenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡